Sarepta Therapeutics (SRPT): Survey Highlights Exondys 51 Opportunity - Baird

November 29, 2016 6:15 AM EST
Get Alerts SRPT Hot Sheet
Price: $34.23 -4.86%

Rating Summary:
    17 Buy, 10 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Sarepta Therapeutic (NASDAQ: SRPT) after connecting with 30 doctors treating DMD patients for their perspectives and expected prescribing patterns for Exondys 51.

Most seem convinced of the drug's efficacy, and plan to start prescribing the drug in the next year. Only a few docs have started prescribing the drug already and use estimates through the end of the year indicate that the consensus sales figure of $7.1M may be understating sales for the drug's first quarter on the market.

No change to the price target of $102.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $36.28 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Robert W Baird

Add Your Comment